anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide skin care soap imparting an adsorbing property, a covering property, and a moisture-retaining function to skin by adding olive oil and sodium hydroxide, or APIREPIHA and sodium hydroxide to goat milk.  <P>SOLUTION: 1. This skin care soap is obtained by dissolving sodium hydroxide to water, heating the solution, adding heated olive oil to the solution with stirring, adding goat milk to the mixture, and then solidifying the product. 2. The skin care soap is obtained by dissolving sodium hydroxide to water, heating the solution, adding APIREPIHA oil to the solution, adding goat milk to the mixture with stirring, and then solidifying the product.  <P>COPYRIGHT: (C)2003,JPO
Lagovirus europaeus/GI.2 causes severe and highly fatal Rabbit Hemorrhagic Disease (RHD). Because of its characteristics, this infection is used as an animal model for acute liver failure (ALF). Apoptosis is one of the key processes underlying ALF and has been described as one of the mechanisms of RHD pathogenesis. Apoptotic cell death has been quite well characterized in infection with different variants of GI.1 strains, but so far, the GI.2 genotype has not been widely studied. In this study, we performed an evaluation of apoptotic cell death in hepatocytes of rabbits infected with Lagovirus europaeus/GI.2. We analyzed the expression of genes involved in apoptotic cell death by real-time PCR and performed immunohistochemical (IHC) assays. We showed a significant increase in the expression of caspase-3 and the proapoptotic Bax and anti-apoptotic Bcl-2 in infected animals. In addition, we recorded increased Bax/Bcl-2 ratios. IHC analyses showed the presence of morphological signs of apoptosis in the hepatocytes of infected rabbits. Our results indicate that caspase-3 and proteins from the Bcl-2 families play a key role in apoptosis induced by Lagovirus europaeus/GI.2 infection.
In the RTU-PO group, the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. This provides a view of the paramedian interlaminar space. The ligamentum flavum and the dura form the posterior complex that can be often visualized as a single hyperechoic structure beneath which lies the hypoechoic intrathecal space. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
Patients receive olaparib as in Arm I. Patients also receive tremelimumab IV over 60 minutes on day 1. Cycles of tremelimumab repeat every 4 weeks for 4 doses and then every 12 weeks for up to 2 years total in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
Vaccines and antiviral therapies are critical for prevention and treatment of viral diseases. Testing of vaccines, antiviral medications, or live virus challenge studies in volunteers may requires knowing whether the subject has been previously infected by the virus. We will recruit healthy persons for this study and screen them for their eligibility to participate in clinical trials of investigational vaccines or antiviral products, investigational studies of licensed products, or live virus challenge studies. In most cases this will involve a medical history, physical examination, and obtaining blood to test for antibodies to the virus being studied in a vaccine or antiviral therapy trial or live virus challenge study. In some cases blood may be tested for viral DNA or RNA and urine, stool, saliva, nasal swab, or nasopharyngeal wash secretions may be tested for viruses or antibodies to the virus. Additional testing, such as an electrocardiogram (EKG), chest radiograph (CXR), and pulmonary function tests (PFTs) may be done. Samples will also be stored for future research. This study should help us to identify a group of volunteers that will be eligible, based on testing for their prior exposure to viruses, to participate in vaccine or antiviral therapy trials, or live virus challenge studies, .conducted by the Laboratory of Infectious Diseases, NIAID at the NIH Clinical Center.
The present invention relates to a Eupatorium spp. extract having anti-obesity effects as a result of decreasing adipocytes and increasing osteoblasts, as well as the effects of preventing bone disease or fractures by increasing osteoblasts and of preventing osteoporosis by decreasing adipocytes and increasing osteoblasts by the same proportion in mesenchymal stem cells. DCM fraction layers of a Eupatorium spp. stem extract collected on a monthly basis and Eupatorium spp. stem extract collected only in September may inhibit the activity of PPARγ, AP2, CD36, adiponectin C/EBPα, and LPL, which serve as significant factors for adipocyte differentiation in C3H10T1/2 cells and primary mesenchymal stem cells, which are pluripotent stem cell lines, and may increase the activity of ALP, osterix, CO1I and RUNX2, which serve as significant factors for osteoblast differentiation. The Eupatorium spp. extract of the present invention exhibits the effects of increasing bone mineral density (BMD) and decreasing adipocytes in bone marrow in an osteoporosis animal model experiment involving an ovariectomy, and therefore may be used as a useful material for preventing and treating osteoporosis.
Chlorthalidone is an oral antihypertensive/diuretic. It is a monosulfamyl diuretic that differs chemically from thiazide diuretics in that a double-ring system is incorporated in its structure. It is 2-Chloro-5(1- hydroxy-3-oxo-1-isoindolinyl) benzenesulfonamide with the following structural formula:

Molecular Formula: C14H11ClN2O4S Molecular Weight: 338.76

Chlorthalidone, USP is practically insoluble in water, in ether, and in chloroform; soluble in methanol; slightly soluble in ethanol.

Chlorthalidone tablets are available containing either 25 mg or 50 mg of chlorthalidone, USP and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, povidone, sodium starch glycolate, D&C Yellow No. 10, magnesium stearate. The 50 mg Tablets also contain FD&C Blue No. 1.

FDA approved dissolution specification differs from that of the USP.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in patients treated with somatropin. Symptoms usually occurred within the first eight (8) weeks after the initiation of somatropin therapy. In all reported cases, IH-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of somatropin dose.

Perform fundoscopic examination before initiating treatment with NGENLA to exclude preexisting papilledema and periodically thereafter. If papilledema is identified prior to initiation, evaluate the etiology and treat the underlying cause before initiating NGENLA. NGENLA should be temporarily discontinued in patients with clinical or fundoscopic evidence of IH. If IH is confirmed, restart treatment with NGENLA at a lower dose after IH-associated signs and symptoms have resolved.
Echinops plants have received great attention for the treatment of many diseases due to pharmacological properties such as their antidiabetic, antioxidant, and anti-inflammatory characteristics. The major purpose of the present study was to investigate the cardioprotective benefits of Echinops cephalotes (Ech) against myocardial ischemia-reperfusion (MI/R) injury. Male Wistar rats were randomly allocated to three groups: sham, MI, and MI + Ech. The left coronary artery (LAD) was blocked for 30 minutes to induce MI. In the treatment group, rats were given 150 mg/kg/day of Ech extract for 28 days. Aqueous extracts were made from Echinops plants. To study heart function, fibrosis, cardiac damage indicators, and oxidative stress factors, echocardiography, Masson's trichrome staining, and biochemical tests were used. The expression of matrix metalloproteinase 2 and 9 (MMP2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP) was determined using Western blotting. Tissue damage was assessed using hematoxylin and eosin staining. MI group exhibited significantly reduced ejection fraction (EF) and fractional shortening (FS), enhanced levels of lactate dehydrogenase (LDH), creatine kinase MB (CK-MB), cardiac Troponin I (cTnI), and malondialdehyde (MDA), as well as a decrease in the Glutathione (GSH) tissue content, reduced activity of superoxide dismutase (SOD), increasing fibrosis, upregulations of MMP-2 and MMP-9, and reduction of TIMP compared to the sham group. The findings suggest that Ech in particular, could be a promising therapeutic agent to reduce the damage in MI by targeting oxidative stress and modulating the activities of matrix metalloproteinases and their tissue inhibitors.
PURPOSE:Neothramycin A and/or neothramycin B are combined with magnesium gluconate and freeze dried to give a neothramycin preparation for injection used as a carcinostatic agent with high stability and solubility. CONSTITUTION:Neothramycin A (R1 is hydroxyl, R2 is H) and/or B (R1 is H, R2 is hydroxyl) are combined with magnesium gluconate and freeze dried to give a neothramycin preparation for injection. For example, magnesium gluconate is dissolved in hot water and the solution is cooled down to room temperature. Then, neothramycin is dissolved and aseptically filtered, an filled in transparent ampules. Then, immediately they are freeze dried and the ampules are sealed by fusing, while a nitrogen gas is flown. The concentration of neothramycin in the solvent is 5-20mg/ml convenient for freeze drying.
Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
BACKGROUND: C-reactive protein (CRP) is a useful negative predictor of infectious complications following colorectal surgery. Whilst a CRP level below reported cut-offs on postoperative day (POD) 3 to 5 can be reassuring, it can be difficult to interpret an elevated CRP above these cut-offs. This study evaluated whether investigating an elevated CRP on POD 3-5 allows earlier detection of infectious complications.
METHODS: Adult patients undergoing elective colonic or rectal resection were prospectively evaluated over two consecutive time periods. Group 1 had CRP levels measured on POD 3-5 with routine clinical care while Group 2 followed an algorithm where CRP levels above certain cut-offs (170 mg/L on POD3, 125 mg/L on POD4, or increase of 50 units from POD 3-4 or POD 4-5) led to an abdominopelvic CT scan and septic screen. Complications were graded as per the Clavien-Dindo classification and Comprehensive Complication Index (CCI).
RESULTS: 120 patients were included in Group 1 and 60 patients were included in Group 2. There were no significant differences between the two groups with regards to patient, operation or disease characteristics. Whilst the overall complication burden was significantly greater in Group 2 (CCI 29.6 versus 12.2, P < 0.001), there were no significant differences between the groups in the day of diagnosis of infectious complication, the overall incidence, or type of complications.
CONCLUSION: Early investigation of an elevated or increasing CRP on POD 3-5 following elective major colorectal surgery did not allow earlier detection of infectious complications.
BACKGROUND: We present a case of a child with Floating-Harbor Syndrome (FHS) with bilateral chorioretinal coloboma (CC). To the best of our knowledge, this is the first case report of this association. Floating- Harbor syndrome is an extremely rare autosomal dominant genetic disorder with approximately 100 cases reported. It is characterized by a series of atypical features that include short stature with delayed bone age, low birth weight, skeletal anomalies, delayed speech development, and dysmorphic facial characteristics that typically portray a triangular face, deep-set eyes, long eyelashes, and prominent nose.
MATERIALS AND METHODS: Our patient was examined by a pediatric ophthalmologist for the time at age of 7. Visual acuity, optical coherence tomography (OCT) and Optos imaging were collected on every visit. The patient had whole genome sequencing ordered by a pediatric geneticist to confirm Floating-Harbor syndrome.
RESULTS: We present the patient's OCT and Optos images that illustrate the location of the patient's inferior chorioretinal coloboma in both eyes. The whole genome sequencing report collected revealed a heterozygous de novo pathogenic variant in the SRCAP gene, consistent with a Floating-Harbor syndrome diagnosis in the literature.
DISCUSSION: Both genetic and systemic findings are consistent with the diagnosis of Floating-Harbor syndrome in our patient. Rubenstein-Taybi and Floating-Harbor syndrome share a similarity in molecular and physical manifestations, but because of the prevalence in Rubenstein-Taybi diagnoses, it is a syndromic condition that includes coloboma and frequently associated with each other. Therefore, a retinal exam should become part of the standard protocol for those with FHS, as proper diagnosis, examination and treatment can prevent irreversible retinal damage.
PURPOSE:To obtain a bathing agent. composition containing alpha2-adrenergic suppressing medicine, capable of providing smoothness to skin and excellent in warm feeling of body. CONSTITUTION:This bathing agent composition contains >=0.005wt.%, preferably 0.01-20wt.% of a beta-adrenergic suppressing medicine selected from yohimbine, phentolamine and ergotamine and theirs salts, etc., and further, inorganic salts (e.g. sodium sulfate), an organic acid (e.g. succinic acid), a carboxylic acid salt (e.g. sodium hydrogen carbonate) and an oily component (e.g. glyceride myristate) are preferably blended therein. The moist feeling of skin and warm feeling of body are further enhanced by combinedly using these ingredients. The concentration of the beta-adrenergic suppressing medicine used in bathing is preferably 0.01-200ppm. The bathing agent composition is used in an amount so as to provide 0.1-200ppm concentration of the p-adrenergic suppressing medicine at a time in bathing.
The rhizomes of Ruscus aculeatus L. (Lileaceae) (butcher's broom or knee holly) are extracted with a satd. aqs. soln. of n-butanol, the butanolic phase is evaporated, the residue is taken up in an alcohol, pref. MeOH, and the saponins precipitated with a suitable agent. The agent used to precipitate the saponins is pref. a mixture of ether and acetone. The crude saponins may be purified by chromatography on an alumina column. Saponins are of use in the pharmaceutical industry.
PURPOSE: Inborn errors of IFN-γ immunity underlie Mendelian susceptibility to mycobacterial disease (MSMD). Twenty-two genes with products involved in the production of, or response to, IFN-γ and variants of which underlie MSMD have been identified. However, pathogenic variants of IFNG encoding a defective IFN-γ have been described in only two siblings, who both underwent hematopoietic stem cell transplantation (HCST).
METHODS: We characterized a new patient with MSMD by genetic, immunological, and clinical means. Therapeutic decisions were taken on the basis of these findings.
RESULTS: The patient was born to consanguineous Turkish parents and developed bacillus Calmette-Guérin (BCG) disease following vaccination at birth. Whole-exome sequencing revealed a homozygous private IFNG variant (c.224 T > C, p.F75S). Upon overexpression in recipient cells or constitutive expression in the patient's cells, the mutant IFN-γ was produced within the cells but was not correctly folded or secreted. The patient was treated for 6 months with two or three antimycobacterial drugs only and then for 30 months with subcutaneous recombinant IFN-γ1b plus two antimycobacterial drugs. Treatment with IFN-γ1b finally normalized all biological parameters. The patient presented no recurrence of mycobacterial disease or other related infectious diseases. The treatment was well tolerated, without the production of detectable autoantibodies against IFN-γ.
CONCLUSION: We describe a patient with a new form of autosomal recessive IFN-γ deficiency, with intracellular, but not extracellular IFN-γ. IFN-γ1b treatment appears to have been beneficial in this patient, with no recurrence of mycobacterial infection over a period of more than 30 months. This targeted treatment provides an alternative to HCST in patients with complete IFN-γ deficiency or at least an option to better control mycobacterial infection prior to HCST.
All participants will receive NBT-NM108 prepared as muffin (each contains 30 g of the product) for 4 weeks. The dosage will be 2 muffins a day. This dosage of NBT-NM108 will provide 24 g/day of dietary fibers.
Peyronie's disease (PD) is a fibrotic condition of the penis, affecting 1-13% of the US male population. The disease results in penile curvature and significant psychosocial bother. Current preferred therapies for PD include repeated penile injections with bacterial enzymes and surgery. However, these therapies are expensive and in some cases result in permanent reductions in penile length and sensation. Penile traction therapy (PTT) is a relatively newer treatment which has been proposed as a treatment for PD with preliminary data suggesting a potential role. However, currently available PTT devices are primarily designed for penile lengthening and have many significant limitations including a requirement of use for 9 hours daily and significant difficulties in personal application. Given these limitations, a new penile traction device (RestoreX® ) was created and funded through Mayo Ventures and was specifically designed to treat men with PD. The primary objective of the current study is to evaluate safety of the device using various dosing schedules, with secondary endpoints designed to assess efficacy and subjective outcomes. To accomplish the study, a population of men from Mayo Clinic with PD will be enrolled and will be randomized to utilize the device for varying amounts of time. Outcomes will be assessed at 3, 6, and 9 months, and results are to be used with the intent to publish in a scientific journal.
The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
PURPOSE:To obtain a new compound having a capillary active effect, useful especially as a base material for a skin care cosmetic, excellent in extension on the skin or affinity to the skin and capable of providing a cosmetic excellent in feeling in use. CONSTITUTION:This compound is expressed by formula I [R is an (un)saturated straight- or branched-chain 1 to 24C hydrocarbon], e.g. 3-O-octyl-1,2- Oisopropylidene-D-glucofuranose. The compound is obtained by reacting 1,2;5,6-di- O-isopropylidene-D-glucofuranose with an etherifying agent (preferably an alkyl chloride, etc.) in the presence of an alkaline substance (preferably NaOH, etc.) and a catalyst composed of a quaternary onium salt (preferably a quaternary ammonium salt such as tetrabutylammonium bromide) and subsequently hydrolyzing the resultant 3-0-alkyl-1,2;5,6-di-O-isopropylidene-D-glucofuranose of formula II at <=450 deg.C. In addition, hydrolysis is conducted recommendably in the presence of an acid in a 1 to 4C alcohol such as methanol.
NEW MATERIAL:The dimethylcyclohexane derivative of formula I (R is CHO, COCH3, CH2OH or group of formula II; the bond containing the dotted line is single or double). EXAMPLE:3,3-Dimethylcyclohexyliden-1-ylacetaldehyde. USE:Useful as perfumery substance. It has the foral, grassy, fruity, musk, citral, hay, fatty, tabacco, or locust nut flavor with woody note, and has excellent durability. PREPARATION:The compound of formula I can be prepared by (1) reacting isophorone of formula III with phosphorus oxychloride in an organic solvent in the presence of N,N'-dimethylformamide, (2) reducing the resultant compound of formula IV with hydrogen in an organic solvent in the presence a base and a reduction catalyst, and (3) condensing the produced compound with e.g. methyl ethyl ketone in the presence of a catalyst.
Dosage must be individualized, depending on the type and severity of the condition to be treated. 

Preferably give the drug when the stomach is empty. If taken soon after eating, nausea and vomiting may occur. 

The usual adult oral dose ranges from 10 to 50 mg three or four times a day. The minimum effective dose is determined by giving 5 to 10 mg initially and repeating the same amount at hourly intervals until satisfactory response occurs, or until a maximum of 50 mg has been given. The effects of the drug sometimes appear within 30 minutes and are usually maximal within 60 to 90 minutes. The drug effects persist for about one hour.

If necessary, the effects of the drug can be abolished promptly by atropine (see OVERDOSAGE).
With an explosive population growth of older adults, the incidence rates of neuropsychiatric syndromes, particularly delirium, are increasing in the community and hospital settings. Delirium is an acute disturbance in cognition and attention that may signify a serious medical, life-threatening condition and may mimic psychiatric-mental health issues. Although its prevalence rate is lower in the community, delirium affects up to 87% of hospitalized older adults and can cost up to $152 billion each year. Despite its common occurrence, delirium is often undetected in 50% to 60% across all care settings, delaying treatment and resulting in poor patient outcomes, such as increased mortality, prolonged hospital stays, cognitive and functional impairment, decreased quality of life, and institutionalization. The current article addresses strategies to recognize delirium and presents evidence-based approaches and future considerations for delirium management. [Journal of Psychosocial Nursing and Mental Health Services, 62(11), 11-18.].
A novel composition and health food having a good pharmacological activity and which can be readily absorbed through an alimentary canal are provided. The composition induced apoptosis of cells and includes an agaricus extract. The composition may further comprise a pharmaceutically acceptable carrier. Typically, the cells are cancer cells. The composition may further include a differentiation inductionagent. Preferably, the differentiation induction agent is a vitamin A derivative. The vitamin A derivative may be tretinoin. The agaricus extract may include a main fraction eluted chromatographically of a molecular weight of 100 to 2000, which is obtained by the steps of extraction with hot water from a fruiting body of agaricus, dialyzing the extract and performing a,chromatography process on the dialyzate.